Fig. 5
From: CD46 targeted 212Pb alpha particle radioimmunotherapy for prostate cancer treatment
Therapeutic effect of a single dose of 212Pb-TCMC-YS5 in the PC3 subcu-CDX model. Red: study group receiving 212Pb-TCMC-YS5. Blue: control group receiving cold YS5 antibody only. Black: no treatment. A Tumor growth within 40 days post treatment of 212Pb-TCMC-YS5 (averaged tumor volumes normalized against tumor volume at day 0). B Tumor growth of individual mouse xenografts within 40 days post treatment of 212Pb-TCMC-YS5 (normalized against tumor volume at day 0). C Body weight post treatment of 212Pb-TCMC-YS5 (averaged body weights normalized against body weight at day 0). D Survival of mice post treatment of 212Pb-TCMC-YS5 (p = 0.001 between the study group and the control group)